Genetics of Mitochondrial Diseases: From Laboratory to the Clinic

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: closed (10 May 2021) | Viewed by 11873

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 00-927 Warsawa, Poland
Interests: human genetics; mitochondrial diseases; mitochondrial genetics; epidemiology of genetic diseases

E-Mail
Guest Editor
1. Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsawa, Poland
2. Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland
Interests: human genetics; mitochondrial diseases; mitochondrial genetics; bioethics

Special Issue Information

Dear Colleagues,

Mitochondrial diseases are a diverse group of metabolic diseases, defined by a defect in oxidative phosphorylation. Most of them affect the central nervous system and muscles, but virtually all organs and systems may be involved. Mitochondrial diseases may be caused by mutations in both the nuclear and the mitochondrial genomes. Mutations in both of them may lead to similar symptoms and the opposite is also true: mutations in the same gene, even the same mutation, may lead to different mitochondrial diseases. In some cases, a primary nuclear mutation causes a defect in the mitochondrial genome as is for example observed in the case of multiple mitochondrial DNA deletions or depletion.

For years, mitochondrial diseases were considered to be very rare, and, due to their extreme phenotypic and genetic variability, difficult to diagnose. The last few years have shown that although still rare, they are much more frequent than was expected, with prevalence reaching 1:5000 in some studies. At the same time, the development of fast massive parallel sequencing technologies has broadened our knowledge of their genetic background revealing new genes involved in the pathology of mitochondrial diseases.

While due to existing sequencing approaches such as panel sequencing or whole exome sequencing, it is easier to obtain the molecular diagnosis, there are still limited therapeutic options. Difficulties with reaching the mitochondria with new therapeutic agents, manipulating the mitochondrial genome and conducting clinical trials impeded by the inability to build homogenous patient groups slow down the progress.

The main achievement in the field of mitochondrial diseases in the last few years was undoubtedly the application of the so-called mitochondrial transfer as a method to prevent the inheritance of mitochondrial DNA mutations leading to devastating disease.

Mitochondrial dysfunction is observed not only in primary mitochondrial diseases but also in other genetic, especially neurological syndromes and numerous multifactorial disorders evoking a question on what is and what is not a mitochondrial disease.

In this issue, we aim to touch on the threads of clinical and genetic diagnosis and treatment of mitochondrial diseases but also ethical issues of new treatment methods and limitations in performing clinical trials are welcome.

Prof. Kasia Tonska
Prof. Ewa Bartnik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mitochondrial diseases
  • mitochondrial genetics
  • genetic analysis
  • therapy of mitochondrial diseases
  • genotype-phenotype correlation

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

17 pages, 3517 KiB  
Article
De Novo Development of mtDNA Deletion Due to Decreased POLG and SSBP1 Expression in Humans
by Yeonmi Lee, Taeho Kim, Miju Lee, Seongjun So, Mustafa Zafer Karagozlu, Go Hun Seo, In Hee Choi, Peter C. W. Lee, Chong-Jai Kim, Eunju Kang and Beom Hee Lee
Genes 2021, 12(2), 284; https://doi.org/10.3390/genes12020284 - 17 Feb 2021
Cited by 8 | Viewed by 3029
Abstract
Defects in the mitochondrial genome (mitochondrial DNA (mtDNA)) are associated with both congenital and acquired disorders in humans. Nuclear-encoded DNA polymerase subunit gamma (POLG) plays an important role in mtDNA replication, and proofreading and mutations in POLG have been linked with [...] Read more.
Defects in the mitochondrial genome (mitochondrial DNA (mtDNA)) are associated with both congenital and acquired disorders in humans. Nuclear-encoded DNA polymerase subunit gamma (POLG) plays an important role in mtDNA replication, and proofreading and mutations in POLG have been linked with increased mtDNA deletions. SSBP1 is also a crucial gene for mtDNA replication. Here, we describe a patient diagnosed with Pearson syndrome with large mtDNA deletions that were not detected in the somatic cells of the mother. Exome sequencing was used to evaluate the nuclear factors associated with the patient and his family, which revealed a paternal POLG mutation (c.868C > T) and a maternal SSBP1 mutation (c.320G > A). The patient showed lower POLG and SSBP1 expression than his healthy brothers and the general population of a similar age. Notably, c.868C in the wild-type allele was highly methylated in the patient compared to the same site in both his healthy brothers. These results suggest that the co- deficient expression of POLG and SSBP1 genes could contribute to the development of mtDNA deletion. Full article
(This article belongs to the Special Issue Genetics of Mitochondrial Diseases: From Laboratory to the Clinic)
Show Figures

Figure 1

15 pages, 4989 KiB  
Article
Progressive External Ophthalmoplegia in Polish Patients—From Clinical Evaluation to Genetic Confirmation
by Biruta Kierdaszuk, Magdalena Kaliszewska, Joanna Rusecka, Joanna Kosińska, Ewa Bartnik, Katarzyna Tońska, Anna M. Kamińska and Anna Kostera-Pruszczyk
Genes 2021, 12(1), 54; https://doi.org/10.3390/genes12010054 - 31 Dec 2020
Cited by 1 | Viewed by 3032
Abstract
Mitochondrial encephalomyopathies comprise a group of heterogeneous disorders resulting from impaired oxidative phosphorylation (OxPhos). Among a variety of symptoms progressive external ophthalmoplegia (PEO) seems to be the most common. The aim of this study is to present clinical and genetic characteristics of Polish [...] Read more.
Mitochondrial encephalomyopathies comprise a group of heterogeneous disorders resulting from impaired oxidative phosphorylation (OxPhos). Among a variety of symptoms progressive external ophthalmoplegia (PEO) seems to be the most common. The aim of this study is to present clinical and genetic characteristics of Polish patients with PEO. Clinical, electrophysiological, neuroradiological, and morphological data of 84 patients were analyzed. Genetic studies of mitochondrial DNA (mtDNA) were performed in all patients. Among nuclear DNA (nDNA) genes POLG was sequenced in 41 patients, TWNK (C10orf2) in 13 patients, and RNASEH1 in 2 patients. Total of 27 patients were included in the chronic progressive external ophthalmoplegia (CPEO) group, 24 in the CPEO+ group. Twenty-six patients had mitochondrial encephalomyopathy (ME), six patients Kearns–Sayre syndrome (KSS), and one patient sensory ataxic neuropathy, dysarthria, ophthalmoparesis (SANDO) syndrome. Genetic analysis of nDNA genes revealed the presence of pathogenic or possibly pathogenic variants in the POLG gene in nine patients, the TWNK gene in five patients and the RNASEH1 gene in two patients. Detailed patients’ history and careful assessment of family history are essential in the diagnostic work-up. Genetic studies of both mtDNA and nDNA are necessary for the final diagnosis of progressive external ophthalmoplegia and for genetic counseling. Full article
(This article belongs to the Special Issue Genetics of Mitochondrial Diseases: From Laboratory to the Clinic)
Show Figures

Figure 1

8 pages, 636 KiB  
Communication
Fourier-Transform Infrared Spectroscopy of Skeletal Muscle Tissue: Expanding Biomarkers in Primary Mitochondrial Myopathies
by Jacopo Gervasoni, Aniello Primiano, Federico Marini, Andrea Sabino, Alessandra Biancolillo, Riccardo Calvani, Anna Picca, Emanuele Marzetti, Silvia Persichilli, Andrea Urbani, Serenella Servidei and Guido Primiano
Genes 2020, 11(12), 1522; https://doi.org/10.3390/genes11121522 - 19 Dec 2020
Cited by 6 | Viewed by 2076
Abstract
Primary mitochondrial myopathies (PMM) are a group of mitochondrial disorders characterized by a predominant skeletal muscle involvement. The aim of this study was to evaluate whether the biochemical profile determined by Fourier-transform infrared (FTIR) spectroscopic technique would allow to distinguish among patients affected [...] Read more.
Primary mitochondrial myopathies (PMM) are a group of mitochondrial disorders characterized by a predominant skeletal muscle involvement. The aim of this study was to evaluate whether the biochemical profile determined by Fourier-transform infrared (FTIR) spectroscopic technique would allow to distinguish among patients affected by progressive external ophthalmoplegia (PEO), the most common PMM presentation, oculopharyngeal muscular dystrophy (OPMD), and healthy controls. Thirty-four participants were enrolled in the study. FTIR spectroscopy was found to be a sensitive and specific diagnostic marker for PEO. In particular, FTIR spectroscopy was able to distinguish PEO patients from those affected by OPMD, even in the presence of histological findings similar to mitochondrial myopathy. At the same time, FTIR spectroscopy differentiated single mtDNA deletion and mutations in POLG, the most common nuclear gene associated with mitochondrial diseases, with high sensitivity and specificity. In conclusion, our data suggest that FTIR spectroscopy is a valuable biodiagnostic tool for the differential diagnosis of PEO with a high ability to also distinguish between single mtDNA deletion and mutations in POLG gene based on specific metabolic transitions. Full article
(This article belongs to the Special Issue Genetics of Mitochondrial Diseases: From Laboratory to the Clinic)
Show Figures

Figure 1

Other

Jump to: Research

13 pages, 1814 KiB  
Case Report
Novel NDUFA13 Mutations Associated with OXPHOS Deficiency and Leigh Syndrome: A Second Family Report
by Adrián González-Quintana, Inés García-Consuegra, Amaya Belanger-Quintana, Pablo Serrano-Lorenzo, Alejandro Lucia, Alberto Blázquez, Jorge Docampo, Cristina Ugalde, María Morán, Joaquín Arenas and Miguel A. Martín
Genes 2020, 11(8), 855; https://doi.org/10.3390/genes11080855 - 26 Jul 2020
Cited by 9 | Viewed by 3055
Abstract
Leigh syndrome (LS) usually presents as an early onset mitochondrial encephalopathy characterized by bilateral symmetric lesions in the basal ganglia and cerebral stem. More than 75 genes have been associated with this condition, including genes involved in the biogenesis of mitochondrial complex I [...] Read more.
Leigh syndrome (LS) usually presents as an early onset mitochondrial encephalopathy characterized by bilateral symmetric lesions in the basal ganglia and cerebral stem. More than 75 genes have been associated with this condition, including genes involved in the biogenesis of mitochondrial complex I (CI). In this study, we used a next-generation sequencing (NGS) panel to identify two novel biallelic variants in the NADH:ubiquinone oxidoreductase subunit A13 (NDUFA13) gene in a patient with isolated CI deficiency in skeletal muscle. Our patient, who represents the second family report with mutations in the CI NDUFA13 subunit, presented with LS lesions in brain magnetic resonance imaging, mild hypertrophic cardiomyopathy, and progressive spastic tetraparesis. This phenotype manifestation is different from that previously described in the first NDUFA13 family, which was predominantly characterized by neurosensorial symptoms. Both in silico pathogenicity predictions and oxidative phosphorylation (OXPHOS) functional findings in patient’s skin fibroblasts (delayed cell growth, isolated CI enzyme defect, decreased basal and maximal oxygen consumption and as well as ATP production, together with markedly diminished levels of the NDUFA13 protein, CI, and respirasomes) suggest that these novel variants in the NDUFA13 gene are the underlying cause of the CI defect, expanding the genetic heterogeneity of LS. Full article
(This article belongs to the Special Issue Genetics of Mitochondrial Diseases: From Laboratory to the Clinic)
Show Figures

Figure 1

Back to TopTop